Takeda Oncology
Cindy Hansen Bradfield is an experienced leader in the oncology pharmaceutical sector with a robust background in sales management and territory leadership. Currently serving as Regional Director - Midwest Solid Tumor at Takeda Oncology since July 2018, Cindy oversees a team of eight Oncology Territory Managers and led major sales restructuring efforts in 2023. Previous roles at Takeda include Regional Director for the Central Midwest Lung & Hematology Portfolio, where Cindy's team won the Takeda Oncology Cup in 2022, and Regional Director for the Midwest Lung Region. Before joining Takeda, Cindy held positions at Merck, Agendia, and Pfizer, excelling in sales and account management. Cindy holds an M.B.A. from Creighton University and a Bachelor's degree in Marketing from the University of Nebraska-Lincoln.
This person is not in any teams
This person is not in any offices
Takeda Oncology
21 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.